BTK substrate profile determined by treating digest KG-1 cell lysate with alkaline phosphatase followed by recombinant BTK. Samples were enriched with PolyMac phosphoenrichment kits prior to analysis.
We have organized our uploaded files into three main folders:
1. BTK KALIP MS raw files: raw mass ...
Using the novel BTK inhibitor PF-303, we model the clinical phenotype of BTK inhibition by systematically examining the impact of PF-303 on the mature immune system in mice autoimmune indications. However, our current knowledge of the role of BTK in immune competence has been gathered in the context...
Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site. While effective at blocking the catalytic ac...
Mast cells are indispensable for LPS-induced septic hypothermia, in which TNF-α plays an essential role to initiate sepsis. Tec family non-receptor tyrosine kinases ITK and BTK regulate mast cell-derived TNF-α in response to allergic antigen, but their role in LPS-induced TNF-α production by mast...
Inhibition of Bruton’s tyrosine kinase (BTK) has proven to be highly effective in the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), autoimmune disorders and multiple sclerosis. Since the approval of the first BTK inhibitor (BTKi), Ibrutinib, several other inhibitors in...
Purpose: to investigate the method of action (MOA) of BTK small molecule inhibitor, G7744, in a pre-clinical mouse lupus model (NZB/W F1). Hypothesis: BTK inhibition will affect B cell and myeloid cell pathways.
The AKT inhibitiontor capivasertib potentiates the efficacy of the BTK inhibitor inhibitor and anti-CD20-based therapeutic regimens acalabrutinib in preclinical models of ABC-DLBCL
